Seeking Alpha

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering...

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering Lovaza eliminates a key upside opportunity, adding that the extent of the impact on growth is unclear at this point. The firm maintains its Neutral rating on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)